📈 Increase in forecast 2025 (currency-adjusted)
- Sales: now €46-48 billion (previously €45-47 billion)
- EBITDA pre exceptionals: €9.7-10.2 billion (previously €9.5-10.0 billion)
- Earnings per share (EPS, adjusted): €4.80-5.30 (previously €4.50-5.00)
- Free cash flow / debt: unchanged
📊 Divisions - Outlook
- Pharmaceuticals: Sales growth 0-3% (previously -4% to -1%), margin 24-26%
- Crop Science: Forecast confirmed
- Consumer Health: Growth at the lower end of +2-5%, margin 23-24
⚖️ US legal disputes
- Provisions by €1.7 billion increased
- Of which €1.2 billion for glyphosate
- €530 million for PCB cases (including SVEC, Seattle)
- Glyphosate lawsuits reduced to 61.000
- Goal: significant defusing of the US disputes by end of 2026
📆 Q2 figures (preliminary)
- Turnover: €10.7 billion
- EBITDA pre exceptionals: €2.1 billion
- Adjusted EPS: €1,23
- Free cash flow: €0.1 billion
- Net financial debt: €33.3 billion
- Special items in EBIT: -€1.0 billion
🔜 Final Q2 results: August 6, 2025